
News|Articles|July 8, 2026
First Half 2026 Recap: Dermatology
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.
Advertisement
Advertisement
The beginning of 2026 represents a notable period in
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
Advertisement
Advertisement

